

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <b>SPRINGER TIMOTHY A</b>			2. Issuer Name and Ticker or Trading Symbol <b>Cartesian Therapeutics, Inc. [ RNAC ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>04/09/2025</b>					
36 WOODMAN ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street) <b>CHESTNUT HILL MA 02467</b>								
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/09/2025		P		7,342	A	\$9.4264 <sup>(1)</sup>	8,628,667	D	
Common Stock	04/09/2025		P		31	A	\$9.9509 <sup>(2)</sup>	8,628,698	D	
Common Stock	04/09/2025		P		41,604	A	\$9.4264 <sup>(1)</sup>	571,402	I	See Footnote <sup>(3)</sup>
Common Stock	04/09/2025		P		178	A	\$9.9509 <sup>(2)</sup>	571,580	I	See Footnote <sup>(3)</sup>
Common Stock	04/10/2025		P		7,966	A	\$10.4345 <sup>(4)</sup>	8,636,664	D	
Common Stock	04/10/2025		P		609	A	\$10.9231	8,637,273	D	
Common Stock	04/10/2025		P		45,144	A	\$10.4345 <sup>(4)</sup>	616,724	I	See Footnote <sup>(3)</sup>
Common Stock	04/10/2025		P		3,451	A	\$10.9231	620,175	I	See Footnote <sup>(3)</sup>
Common Stock	04/11/2025		P		6,412	A	\$10.7726 <sup>(5)</sup>	8,643,685	D	
Common Stock	04/11/2025		P		36,338	A	\$10.7726 <sup>(5)</sup>	656,513	I	See Footnote <sup>(3)</sup>
Common Stock								330,695	I	By wife

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$8.95 to \$9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$9.95 to \$9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$9.918 to \$10.7461. The Reporting Person undertakes to provide

upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.  
5. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$10.395 to \$11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

**Remarks:**

[/s/ Matthew Bartholomae,](#)  
[Attorney-in-Fact for Timothy](#) [04/11/2025](#)  
[A. Springer](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**